Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment

Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment

Anaïs Pujals,1–3,* Loëtitia Favre,4,* Philippe Gaulard,1–3 Joëlle Wiels41Department of Pathology, Assistance Publique-Hôpitaux de Paris, CHU Henri Mondor, 2Faculté de Médecine, Université Paris-Est Cr&eacut...

Full description

Bibliographic Details
Main Authors: Pujals A, Favre L, Gaulard P, Wiels J
Format: Article
Language:English
Published: Dove Medical Press 2015-07-01
Series:Blood and Lymphatic Cancer: Targets and Therapy
Online Access:http://www.dovepress.com/activation-of-wild-type-p53-by-mdm2-inhibitors-a-new-strategy-for-lymp-peer-reviewed-article-BLCTT

Internet

http://www.dovepress.com/activation-of-wild-type-p53-by-mdm2-inhibitors-a-new-strategy-for-lymp-peer-reviewed-article-BLCTT

Similar Items